

# RESEARCHING ALZHEIMER'S MEDICINES

## SETBACKS AND STEPPING STONES

Alzheimer's disease is a devastating illness which places significant burden not only on patients and their caregivers, but the health care system and the economy. Much of the burden is placed disproportionately on the elderly, women and people of color. As the aging population continues to grow, so does the need to address and conquer this disease. However, research in neurological diseases like Alzheimer's is exceptionally challenging and characterized by many setbacks. These setbacks can lead to new learnings that advance our research efforts and bring us one step closer to conquering this devastating disease.

### Society's Great Challenge



**More than 6 million** Americans impacted



**6th leading** cause of death in the U.S.



**\$355 billion** each year in direct medical costs




**More than 11 million caregivers** providing **\$257 billion** in uncompensated care



**Black Americans are twice as likely** and **Latinos are 1.5 times more likely** to develop Alzheimer's than non-Hispanic white Americans

Source: Alzheimer's Association. [Facts & Figures](#).

### Unsuccessful Investigational Alzheimer's Drugs by Phase (1998-2021)



■ Phase 0, 1/2  
■ Phase 2, 2/3  
■ Phase 3, Reg Review  
■ Phase Unknown

Source: PhRMA Analysis of Adis R&D Insight Database. May 2021.

Setbacks in Alzheimer's disease medicine development highlight the complexity of Alzheimer's research — there is just a 2% success rate in treatments. It's important to recognize that with these so-called failures comes new information that brings us one step closer to a disease-modifying medicine.

### Key Challenges



Significant **gap in scientific knowledge**



**Constraints** of preclinical models



Complexities of **clinical trial design**

Source: PhRMA. [Researching Alzheimer's Medicines: Setbacks and Stepping Stones](#).

### Hope on the Horizon

A robust pipeline of medicines in development represents our greatest hope in combatting Alzheimer's disease.



**83 new medicines** in clinical development by biopharmaceutical companies



**82.5%** are potentially disease modifying



New treatment approved by 2025 that **delays onset** by five years could reduce costs by **\$367 billion** a year by 2050

Sources:

PhRMA Analysis of Adis R&D Insight Database. May 2021.

Alzheimer's Association. [Trajectory Report](#).

Alzheimer's Association. [Alzheimer's disease drug development pipeline: 2021](#).